Clinical Trials Directory

Trials / Terminated

TerminatedNCT00602147

Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

Genetic Analysis of Toxicity Associated With High-Dose Melphalan

Status
Terminated
Phase
Study type
Observational
Enrollment
95 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment. PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.

Detailed description

OBJECTIVES: * To determine whether single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters are associated with the development and/or severity of mucositis in patients with multiple myeloma receiving high-dose melphalan. * To determine whether SNPs in genes that influence melphalan metabolism are associated with the development and/or severity of mucositis in these patients. OUTLINE: This is a multicenter study. Blood or mouthwash samples are collected and DNA isolated from these specimens is analyzed for single nucleotide polymorphisms (SNPs) in LAT1 or other candidate genes. Public databases (i.e., dbSNP and HapMap) are reviewed to select representative SNPs for genotype analysis.

Conditions

Interventions

TypeNameDescription
OTHERlaboratory biomarker analysisBlood or cheek cells wil be collected.

Timeline

Start date
2007-07-01
Primary completion
2009-01-01
Completion
2010-04-01
First posted
2008-01-28
Last updated
2013-03-14

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00602147. Inclusion in this directory is not an endorsement.